PolyActiva Raises $25M and Appoints New CEO to Accelerate U.S. Growth and Advance Ocular Drug Delivery Platform

Fort Worth, TX, June 18, 2025 (Business Wire) -- PolyActiva appointed Jerry St. Peter as CEO and raised $25 million in Series C funding to drive U.S. market expansion and late-stage clinical development of its lead ocular implant, PA5108. The biodegradable drug delivery system has shown promising long-term efficacy in reducing intraocular pressure for glaucoma patients. This milestone supports PolyActiva’s transformation into a global player in ophthalmology and expands the potential of its proprietary PREZIA™ technology.

Read full article here.